SCHEMBL6893925

SCHEMBL6893925

CCCN1CCOCC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PER2 O15055 2/20 0.37
POLB P06746 2/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
CRY2 Q49AN0 1/20 0.36
GAA P10253 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDK2 Q15119 1/20 0.35
EPHX2 P34913 1/20 0.34
USP19 O94966 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
AOC2 O75106 1/20 0.32
AR P10275 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11701401 0.89 TSHR (0.39) PER2POLBPRMT5WDR77CRY2
SCHEMBL3970458 0.87 ALDH1A1 (0.41) PER2PRMT5WDR77GAASMN1; SMN2
Hydrochloric Acid SCHEMBL28905052 0.84 MGLL (0.39) GAASMN1; SMN2TSHRALDH1A1KMT2A
SCHEMBL4600250 0.83
SCHEMBL24068422 0.83 OPRM1 (0.34) PER2POLBPRMT5WDR77CRY2
SCHEMBL1446194 0.82 PRMT5 (0.38) PER2POLBPRMT5WDR77CRY2
SCHEMBL29341870 0.80 PDK2 (0.39) PER2POLBPRMT5WDR77CRY2
SCHEMBL1446411 0.80 PRMT5 (0.37) PER2POLBPRMT5WDR77CRY2
SCHEMBL21329587 0.80 F10 (0.37) PER2POLBPRMT5WDR77CRY2
SCHEMBL31126065 0.80 POLB (0.40) PER2POLBPRMT5WDR77CRY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023218410-A1 METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR BEIGENE SWITZERLAND GMBH (CH) 2023-11-16 WO disclosed
US-20230331691-A1 TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME Corsair Pharma, Inc. 2023-10-19 US disclosed
US-20230331691-A1 TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME Corsair Pharma, Inc. 2023-10-19 US disclosed
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 US disclosed
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 US disclosed
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
WO-2022269508-A1 PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN NOVARTIS AG (CH) 2022-12-29 WO disclosed
WO-2022256489-A1 METHODS OF TREATING B-CELL MALIGNANCY USING BCL-2 INHIBITOR BEIGENE, LTD. (KY) 2022-12-08 WO disclosed
WO-2021110102-A1 METHODS OF CANCER TREATMENT USING BCL-2 INHIBITOR BEIGENE, LTD. (KY) 2021-06-10 WO disclosed
US-8288381-B2 N-9 substituted purine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-10-16 US disclosed
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2011-10-20 US disclosed
US-8022059-B2 Indazole acrylic acid amide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-20 US disclosed
US-20110098293-A1 Inhibitors of Protein Tyrosine Kinase Activity OTSUKA PHARMACEUTICAL CO. LTD. (JP) 2011-04-28 US disclosed
US-20110086841-A1 N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2011-04-14 US disclosed
US-7902357-B2 Process for the preparation of delmopinol and derivatives thereof SINCLAIR PHARMACEUTICALS LIMITED (GB) 2011-03-08 US disclosed
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 US disclosed
US-20100222579-A1 Process for the Preparation of Delmopinol and Derivatives Thereof ARTUS SURROCA JUAN JOSE 2010-09-02 US disclosed
US-20100028299-A1 Methods and compositions of treating a flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2010-02-04 US disclosed
US-20090137798-A1 Process for the Preparation of Delmopinol and Derivatives Thereof SINCLAIR PHARMACEUTICALS LIMITED (GB) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086841-A1 N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE ADORA3, ADORA2A, ADORA2B PER2 4391/4885POLB 765/4885PRMT5 800/4885
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS ITGB6, ITGA5, ITGAV PER2 3809/4885POLB 4588/4885PRMT5 292/4885
US-20230331691-A1 TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME PTGIS, PTGIR, PTGER3 PER2 2591/4885POLB 907/4885PRMT5 1802/4885
US-20100222579-A1 Process for the Preparation of Delmopinol and Derivatives Thereof MDN1, MCOLN3, EML4 PER2 3157/4885POLB 2346/4885PRMT5 2142/4885
US-20090137798-A1 Process for the Preparation of Delmopinol and Derivatives Thereof MDN1, MCOLN3, EML4 PER2 3141/4885POLB 2381/4885PRMT5 2060/4885
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity ERBB2, ABL1, FLT1 PER2 2117/4885POLB 2199/4885PRMT5 1017/4885
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF ADORA2A, ADORA2B, ADORA3 PER2 1980/4885POLB 577/4885PRMT5 3242/4885
US-20110098293-A1 Inhibitors of Protein Tyrosine Kinase Activity ABL1, ERBB2, TYRO3 PER2 1985/4885POLB 2215/4885PRMT5 1000/4885
US-20100028299-A1 Methods and compositions of treating a flaviviridae family viral infection EIF2AK2, NSUN3, NSUN2 PER2 1369/4885POLB 582/4885PRMT5 1121/4885
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND KCNH2, KCNH3, KCNJ11 PER2 2442/4885POLB 4032/4885PRMT5 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.